LRG1 Protein Discovery: New Hope for Preventing Diabetic Retinopathy & Vision Loss

A newly identified protein, LRG1, appears to play a critical role in the earliest stages of diabetic retinopathy, a leading cause of vision loss among working-age adults. This discovery, spearheaded by researchers at the UCL Institute of Ophthalmology, offers a potential new avenue for preventing blindness in millions living with diabetes by intervening before irreversible damage occurs. The findings, published in Science Translational Medicine, suggest a shift in how the disease is approached – from managing late-stage damage to proactively protecting vision.

Early Damage and the Role of LRG1

Diabetic retinopathy develops when high blood sugar levels damage the blood vessels in the retina. For years, the protein VEGF has been the primary target of treatments for this condition. However, current therapies focusing on VEGF are only effective in roughly half of patients and often arrive into play after significant damage has already taken place. This new research indicates that LRG1 initiates the damaging process much earlier than previously understood.

Researchers found that LRG1 causes the cells surrounding the eye’s smallest blood vessels to constrict excessively, effectively ‘squeezing’ them. This constriction reduces the vital oxygen supply to the retina, setting off a cascade of events that can ultimately lead to long-term visual impairment. Crucially, in experiments using mouse models of diabetes, blocking the activity of LRG1 prevented this early damage and preserved healthy eye function. UCL’s report on the study details these findings.

Beyond Mouse Models: Implications for Human Treatment

Dr. Giulia De Rossi, Senior Research Fellow at UCL and lead author of the study, emphasized the significance of the discovery: “Our discovery shows that diabetic eye disease starts earlier than we thought, and LRG1 is a key culprit in this early damage. Targeting this protein could give us a way to protect vision before serious damage occurs and prevent, rather than treat, blindness in millions of people living with diabetes.”

The research team has already developed a drug specifically designed to target LRG1. This therapeutic has undergone preliminary testing and is currently undergoing further preclinical research, paving the way for potential human clinical trials in the near future. ScienceDaily’s coverage highlights the potential for this treatment to prevent vision loss before symptoms even appear.

Why This Discovery Matters for People with Diabetes

Diabetic retinopathy affects individuals with both type 1 and type 2 diabetes. The insidious nature of the early stages of the disease means that damage can accumulate without noticeable symptoms. By the time blurred or distorted vision appears, irreversible harm may already be done. This is why the identification of LRG1 as an early trigger is so promising. A treatment that intervenes at this stage could potentially halt the progression of the disease altogether.

The potential benefits extend beyond those with existing retinopathy. Researchers believe that targeting LRG1 could even prevent the development of the condition in the first place, offering a proactive approach to vision protection for the growing global population with diabetes. Diabetes UK’s news release underscores the potential to protect the sight of millions worldwide.

The Path to Clinical Trials and Future Research

The current research builds on years of investigation into the role of LRG1 in ocular disease by scientists at the UCL Institute of Ophthalmology. Professors John Greenwood and Stephen Moss were instrumental in first identifying LRG1’s involvement in eye health. Their function led to the founding of Senya Therapeutics, a UCL spinout company dedicated to developing drugs that target LRG1, with support from UCL Business.

Professor Greenwood, a world expert in LRG1 biology, stated: “This study delivers vital insight into the disease and shows that therapeutic targeting of LRG1 has real clinical potential. The discovery that LRG1 is an early initiating factor driving diabetic retinopathy is enormously exciting.” Professor Emeritus Moss added that the existing LRG1 therapeutic, already developed, could offer a new option for patients, particularly those in the early stages of the disease who don’t respond to current treatments.

What Comes Next: From Preclinical to Patient Care

The next steps involve rigorous testing of the LRG1-targeting drug in human clinical trials. These trials will be crucial in determining the safety and efficacy of the treatment. Researchers will necessitate to carefully assess the optimal dosage, potential side effects, and long-term benefits. The process of bringing a new drug to market is lengthy and complex, involving multiple phases of clinical trials and regulatory review.

Dr. Ailish Murray, director of grants and research at Moorfields Eye Charity, highlighted the importance of this research in addressing the challenges of early detection: “The early stages of diabetic retinopathy are often difficult to detect, leaving many people with irreversible damage once the symptoms have occurred. This research offers an key and vital next step in helping to prevent this disease, offering the chance to save the sight of millions of people living with diabetes now and in the future.”

Morag Foreman, head of discovery researchers at Wellcome, added: “This is an exciting breakthrough, lighting a potential path towards treatment for diabetic eye disease. These findings are a result of cutting-edge discovery research and demonstrate the importance of backing early science that could translate to meaningful advances in medicine.”